PHARMACEUTICAL giant Sanofi's decision to refund the unused Dengvaxia vaccines will not affect the investigation into the controversial dengue vaccination program, Malacanang said on Tuesday.

Palace spokesman Harry Roque gave the assurance after Sanofi agreed to the demand of the Department of Health (DoH) to refund the cost of the unused vials of Dengvaxia which, Secretary Francisco Duque said, was estimated at P1.4 billion or $27.8 million.

Premium + Digital Edition

Ad-free access


P 80 per month
(billed annually at P 960)
  • Unlimited ad-free access to website articles
  • Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)

TRY FREE FOR 14 DAYS
See details
See details